TY - JOUR
T1 - Carbon nanotubes as vaccine scaffolds
AU - Scheinberg, David A.
AU - McDevitt, Michael R.
AU - Dao, Tao
AU - Mulvey, J. Justin
AU - Feinberg, Evan
AU - Alidori, Simone
N1 - Funding Information:
This work was supported by NIH P01 Ca23766 and NIH R01 Ca55349 , the Experimental Therapeutics Center , and the Tudor and Glades foundations .
PY - 2013/12
Y1 - 2013/12
N2 - Carbon nanotubes display characteristics that are potentially useful in their development as scaffolds for vaccine compositions. These features include stability in vivo, lack of intrinsic immunogenicity, low toxicity, and the ability to be appended with multiple copies of antigens. In addition, the particulate nature of carbon nanotubes and their unusual properties of rapid entry into antigen-presenting cells, such as dendritic cells, make them especially useful as carriers of antigens. Early attempts demonstrating carbon nanotube-based vaccines can be used in both infectious disease settings and cancer are promising.
AB - Carbon nanotubes display characteristics that are potentially useful in their development as scaffolds for vaccine compositions. These features include stability in vivo, lack of intrinsic immunogenicity, low toxicity, and the ability to be appended with multiple copies of antigens. In addition, the particulate nature of carbon nanotubes and their unusual properties of rapid entry into antigen-presenting cells, such as dendritic cells, make them especially useful as carriers of antigens. Early attempts demonstrating carbon nanotube-based vaccines can be used in both infectious disease settings and cancer are promising.
KW - Adjuvants
KW - Antigen presenting cells
KW - Carbon nanotubes
KW - Vaccines
UR - http://www.scopus.com/inward/record.url?scp=84888868158&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84888868158&partnerID=8YFLogxK
U2 - 10.1016/j.addr.2013.07.013
DO - 10.1016/j.addr.2013.07.013
M3 - Review article
C2 - 23899863
AN - SCOPUS:84888868158
SN - 0169-409X
VL - 65
SP - 2016
EP - 2022
JO - Advanced Drug Delivery Reviews
JF - Advanced Drug Delivery Reviews
IS - 15
ER -